Table 2.
Characteristics of the participants in the included studies
| Study ID | Groups | Number | Male (%) | Age (median) | Smoking Status | Histopathology | ECOG performance status | Tumor stage | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Former | Current | Never | SCC | ADC | ASC | Other | 0 | 1 | Locally advanced (IIIB) | Metastatic (IV) | |||||
| Li et al. 2022 [18] |
TS + CT CT |
33 33 |
15 (45.4) 14 (42.4) |
65.74 (59–78) 65.58 (58–78) |
N/A N/A |
N/A N/A |
N/A N/A |
0 0 |
33 (100) 33 (100) |
0 0 |
0 0 |
N/A N/A |
N/A N/A |
N/A N/A |
N/A N/A |
| Lu et al. 2021 [19] |
TS + CT CT |
223 111 |
168 (75.3) 79 (71.2) |
60 (27–75) 61 (25–74) |
115 (51.6) 53 (47.7) |
32 (14.3) 13 (11.7) |
76 (34.1) 45 (40.5) |
N/A N/A |
215 (96.4) 107 (96.4) |
1 (0.4) 2 (1.8) |
7 (3.1) 2 (1.8) |
54 (24.2) 24 (21.6) |
169 (75.8) 87 (78.4) |
40 (17.9) 21 (18.9) |
183 (82.1) 90 (81.1) |
| Wang et al. 2021 [20] |
Arm A: TS + CT (PTX + CBP) Arm B: TS + CT (nab PTX + CBP) Arm C: CT (PTX + CBP) |
120 119 121 |
107 (89.2) 112 (94.1) 111 (91.7) |
60 (41–74) 63 (38–74) 62 (34–74) |
96 (80.0) 107 (89.9) 98 (81.0) |
24 (20.0) 12 (10.1) 23 (19.0) |
TS + CT: 239 (100) CT: 121 (100) |
N/A N/A |
N/A N/A |
N/A N/A |
31 (25.8) 22 (18.5) 32 (26.4) |
89 (74.2) 97 (81.5) 89 (73.6) |
38 (31.7) 40 (33.6) 44 (36.4) |
82 (68.3) 79 (66.4) 77 (63.6) |
|
| Zhou et al. 2022 [21] |
TS CT |
535 270 |
416 (77.8) 206 (76.3) |
61.0 (28–88) 61.0 (32–81) |
373 (69.7) 188 (69.6) |
162 (30.3) 82 (30.4) |
248 (46.4) 122 (45.2) |
N/A N/A |
N/A N/A |
N/A N/A |
116 (21.7) 50 (18.5) |
419 (78.3) 220 (81.5) |
84 (15.7) 33 (12.2) |
451 (84.3) 237 (87.8) |
|
Abbreviations: TS: tislelizumab; CT: chemotherapy; PTX: paclitaxel; CBP: carboplatin; SCC: squamous cell carcinoma; ADC: adenocarcinoma; ASC: adenosquamous carcinoma; ECOG: Eastern Cooperative Oncology Group; N/A: not available